Aquestive Therapeutics: Five Foci For 2025
Portfolio Pulse from
Aquestive Therapeutics is on the verge of FDA approval for Anaphylm, which could disrupt the U.S. anaphylaxis market. AQST-108 shows promise for alopecia areata, and Libervant has gained orphan drug exclusivity, ensuring market exclusivity until 2031.
January 06, 2025 | 5:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market. AQST-108 shows promise for alopecia areata, and Libervant has gained orphan drug exclusivity, ensuring market exclusivity until 2031.
The potential FDA approval of Anaphylm could significantly impact Aquestive's market position by entering the anaphylaxis market dominated by EpiPen. AQST-108's promising results for alopecia areata and Libervant's orphan drug exclusivity until 2031 provide strong future revenue streams.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100